Drug Profile
Research programme: CD66 antigen inhibitors - cCAM Biotherapeutics
Alternative Names: CM-10; MRG 1Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator cCAM Biotherapeutics
- Class Monoclonal antibodies
- Mechanism of Action CD66 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Malignant melanoma; Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Malignant-melanoma(Metastatic disease) in Israel (IV, Injection)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Israel (IV, Injection)
- 01 Sep 2012 Preclinical trials in Malignant melanoma (metastatic disease) in Israel (IV)